EU Panel Backs Polatuzumab Vedotin Approval for DLBCL

13:38 EST 15 Nov 2019 | OncLive

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the antibody-drug conjugate polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for a hematopoietic stem cell transplant.

Original Article: EU Panel Backs Polatuzumab Vedotin Approval for DLBCL


More From BioPortfolio on "EU Panel Backs Polatuzumab Vedotin Approval for DLBCL"

Quick Search

Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...